ALK1 as an emerging target for antiangiogenic therapy of cancer.
Open accessThe DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
Members of the TGF-β family act on many, if not all, cell types within the body, producing diverse and complex cellular outcomes. Activation of the endothelial cell-restricted TGF-β type I receptor ALK1 results from the binding of several different ligands of the TGF-β family, including bone morphogenetic protein (BMP) 9, BMP10, and TGF-β. Mounting genetic, pharmacologic, and histopathologic evidence supports a critical role for ALK1 signaling in regulation of both developmental and pathologic blood vessel formation. However, the precise function of TGF-β family signaling in endothelial cells is difficult to predict and appears highly context dependent because of the multitude of ligands and receptors influencing the final outcome. Pharmacologic inhibitors of ALK1 have recently been developed and will allow for more accurate studies of ALK1 function in vivo, as well as for assessment of ALK1 as a target for suppression of angiogenesis during tumor development. Herein, we will summarize the current view of ALK1 regulation of endothelial cell phenotype in vitro and in vivo as well as provide an outlook for the ongoing clinical trials of ALK1 inhibitors in malignant disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TGF-β can provide an escape route for tumor angiogenesis by influencing and regulating tumor angiogenesis [218].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [218]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism of activation of the TGF-β receptor
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., & Massagué, J. (1994) · Nature · doi:10.1038/370341a0 · Cited by 2,337
Massagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrel, J., et al. (1994) · Nature Genetics · doi:10.1038/ng1294-345 · Cited by 1,482
TGFβ–SMAD signal transduction: molecular specificity and functional flexibility
Schmierer, B., & Hill, C. S. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2297 · Cited by 1,271
TGFβ signalling: a complex web in cancer progression
Ikushima, H., & Miyazono, K. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2853 · Cited by 1,173
The Human Protein Atlas—a tool for pathology
Pontén, F., Jirström, K., & Uhlen, M. (2008) · The Journal of Pathology · doi:10.1002/path.2440 · Cited by 1,130
Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors
Goumans, M.-J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1743 · Cited by 1,123
Johnson, D. W., Berg, J. N., Baldwin, M. A., Gallione, C. J., Marondel, I., Yoon, S.-J., Stenzel, T. T., Speer, M., Pericak-Vance, M. A., Diamond, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0696-189 · Cited by 1,116
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4
Nakao, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5353 · Cited by 1,070
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism
Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D., & Peterson, R. T. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.54 · Cited by 1,034
Cited by
Zhen, G., Wen, C., Jia, X., Li, Y., Crane, J. L., Mears, S. C., Askin, F. B., Frassica, F. J., Chang, W., Yao, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3143 · Cited by 943
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
Wang, X., Abraham, S., McKenzie, J. A. G., Jeffs, N., Swire, M., Tripathi, V. B., Luhmann, U. F. O., Lange, C. A. K., Zhai, Z., Arthur, H. M., et al. (2013) · Nature · doi:10.1038/nature12345 · Cited by 539
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway
Larrivée, B., Prahst, C., Gordon, E., del Toro, R., Mathivet, T., Duarte, A., Simons, M., & Eichmann, A. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.02.005 · Cited by 359
Cui, Z., Crane, J., Xie, H., Jin, X., Zhen, G., Li, C., Xie, L., Wang, L., Bian, Q., Qiu, T., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207923 · Cited by 268
Metadata
- Authors
- Cunha, S. I., & Pietras, K.
- Affiliations
- Karolinska Institutet (SE)
- ORCID
- Pietras, Kristian
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-06-30
- Volume
- 117
- Issue
- 26
- Pages
- 6999-7006
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3143549
- OpenAlex
- W2078139160
- Cited by
- 184
- References
- 90
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 18 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 16 · 2017: 17 · 2016: 12 · 2015: 16 · 2014: 10 · 2013: 26 · 2012: 10
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ludwig Institute for Cancer Research
- Acceleron
- Cancerfonden
- Karolinska Institutet
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Keywords
- ALK1, TGF-beta type I receptor, anti-angiogenic therapy, tumor angiogenesis, BMP9, BMP10, TGF-beta signaling, endothelial cells, tumor vascularization
- MeSH terms
- Animals, Humans, Ligands, Neoplasm Proteins, Neoplasms, Signal Transduction, Angiogenesis Inhibitors, Activin Receptors, Type II, Endothelial Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ALK1 as an emerging target for antiangiogenic therapy of cancer. https://app.cochat.ai/papers/10.1182/blood-2011-01-330142
- The paper
- Cunha, S. I., & Pietras, K. (2011). ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. https://doi.org/10.1182/blood-2011-01-330142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.